Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion  by Gazoni, Leo M. et al.
A
i
p
L
J
Cardiothoracic Transplantation Gazoni et al
1
TXdditive protection against lung ischemia-reperfusion
njury by adenosine A2A receptor activation before
rocurement and during reperfusion
eo M. Gazoni, MD,a Victor E. Laubach, PhD,a Daniel P. Mulloy, BS,a A. Bellizzi, MD,b Eric B. Unger, BS,aoel Linden, PhD,c Peter I. Ellman, MD,a Turner C. Lisle, MD,a and Irving L. Kron, MDa
O
i
m
3
r
r
M
u
(
p
R
d
m
c
n
c
a
A
C
g
i
a
l
p
t
s
A
t
3
t
m
3
c
pFrom the Departments of Surgery,a Pa-
thology,b and Medicine/Cardiovascular Re-
search Center,c University of Virginia,
Charlottesville, Va.
Research funded by National Institutes of
Health Grant RO1 HL 056093 and National
Institutes of Health Training Grant 5 T32
HL007849.
Drs Linden and Kron are shareholders in
Adenosine Therapeutics, LLC, the corpora-
tion that provided the adenosine 2A recep-
tor agonist ATL-313.
Read at the Eighty-seventh Annual Meeting
of The American Association for Thoracic
Surgery, Washington, DC, May 5–9, 2007.
Received for publication May 4, 2007; re-
visions received July 20, 2007; accepted for
publication Aug 1, 2007.
Address for reprints: Leo M. Gazoni, MD,
Department of Surgery, University of Vir-
ginia Health System, Charlottesville, VA
22908. (E-mail: lmg2x@virginia.edu).
J Thorac Cardiovasc Surg 2008;135:156-65
0022-5223/$34.00
Copyright © 2008 by The American Asso-
ciation for Thoracic Surgery
Dr Gazonii
doi:10.1016/j.jtcvs.2007.08.041
56 The Journal of Thoracic and Cardiobjective: Adenosine A2A receptor activation during reperfusion improves lung
schemia-reperfusion injury. In this study we sought to determine whether pretreat-
ent of rabbits with a potent and selective adenosine A2A receptor agonist, ATL-
13, before transplantation or whether adding ATL-313 to the preservation solution
esults in equivalent or additional protection compared with ATL-313 added during
eperfusion.
ethods: An isolated, ventilated, ex vivo blood-perfused rabbit lung model was
sed. All groups underwent 2 hours of reperfusion after 18 hours of cold ischemia
4°C). ATL-313 was administered 1 hour before ischemia intravenously, with the
reservation solution, and/or during reperfusion.
esults: Both pretreatment of donor animals with ATL-313 or adding ATL-313 just
uring reperfusion improved pulmonary function, but significantly greater improve-
ent was observed when pretreatment and treatment during reperfusion were
ombined (all P  .05). Myeloperoxidase levels, bronchoalveolar lavage tumor
ecrosis factor  levels, and pulmonary edema were all maximally decreased in the
ombined treatment group. The administration of an equimolar amount of the potent
nd highly selective adenosine 2A receptor antagonist, ZM 241385, along with
TL-313, resulted in the loss of protection conferred by ATL-313.
onclusions: Adenosine A2A receptor activation with ATL-313 results in the
reatest protection against lung ischemia-reperfusion injury when given before
schemia and during reperfusion. Improved pulmonary function observed with
denosine A2A receptor activation was correlated with decreased bronchoalveolar
avage tumor necrosis factor  and decreased lung myeloperoxidase. The loss of
rotection observed with the concurrent administration of the adenosine A2A recep-
or antagonist, ZM 241385, supports that the mechanism of ATL-313 protection is
pecifically mediated via adenosine A2A receptor activation.
lthough the yearly number of lung transplants worldwide has increased
130-fold over the past 20 years, critical shortages in the donor pool exist,
and survivals remain low.1 In most series, 30-day mortality rates are close
o 15%, and approximately 33% of patients who receive a lung transplant die within
 years.2,3 Lung ischemia-reperfusion injury (LIRI) after lung transplantation con-
inues to be one of the most common and significant causes of morbidity and
ortality and has been found to increase the risk of bronchiolitis obliterans.4 The
0-day mortality of recipients who have reperfusion injury is as high as 40%
ompared with 7% in patients without graft failure.2,4 Improvements in the care of
atients with end-stage lung disease hinge on the ability to attenuate the robust
nflammatory response characteristic of LIRI.
vascular Surgery ● January 2008
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TXAdenosine potentially plays a critical role in minimizing
schemia-reperfusion (IR) injury inasmuch as it is known to
onfer protection against IR in the lungs, heart, liver, and
idney secondary to its widely described anti-inflammatory
ffects.5,6 The adenosine A2A receptor (A2AR), one of four
ubtypes of the G protein–coupled adenosine receptor fam-
ly that includes A1, A2A, A2B, and A3, has been associated
ith many anti-inflammatory properties. Adenosine recep-
or subclassification has shown specifically that activation
f the A2AR and resultant increases in cyclic adenosine
onophosphate prevent leukocyte adhesion to endothelial
ells as well as inhibiting the release of toxic oxygen prod-
cts and inflammatory cytokines.5,6 The A2AR is predomi-
antly expressed on inflammatory cells including neutro-
hils, mast cells, macrophages, monocytes, and platelets.7
urrent evidence supports diverse mechanisms of IR injury
nd complex interactions between the aforementioned in-
ammatory cells.
Whereas the anti-inflammatory and tissue-protective ef-
ects of A2AR activation during reperfusion are well docu-
ented, protective effects of activating the A2AR in donor
nimals before transplantation have not been reported. Our
roup has previously shown that A2AR activation during
abbit lung reperfusion reduces IR injury after lung trans-
lantation.8,9 Pretreatment of donor lung before ischemia,
owever, may confer better protection. Brief periods of
schemic insult before prolonged ischemia, commonly re-
erred to as ischemic preconditioning, protect against IR
njury and can be pharmacologically manipulated through
ctivation of its key mediators.10 Growing evidence sup-
orts the emerging role of adenosine as one of these key
ediators as the accumulation of adenosine from the break-
own of adenosine triphosphate is a natural method of
rotection against ischemia and inflammation.11,12 In this
tudy we examined the effect of pretreatment of donor
nimals with the highly selective A2AR agonist, ATL-313,
n the development of LIRI. We hypothesized that activa-
ion of A2AR in the lung before ischemia might lead to
nhanced protection compared with A2AR activation during
Abbreviations and Acronyms
A2AR  A2A receptor
ANOVA  analysis of variance
BAL  bronchoalveolar lavage
ELISA  enzyme-linked immunosorbent assay
IR  ischemia-reperfusion
LIRI  lung ischemia-reperfusion injury
MPO myeloperoxidase
PA  pulmonary artery
TNF-   tumor necrosis factor eperfusion alone. T
The Journal of Thoracicaterials and Methods
nimal Care
ew Zealand White rabbits (Burleson Enterprises, Inc, Unionville,
a) of both sexes (3.0–3.5 kg) were used for all studies and
eceived humane care in accordance with the “Guide for the Care
nd Use of Laboratory Animals” published by the National Insti-
utes of Health (NIH publication No.85-23, revised 1995). The
nimal Care and Use Committee at the University of Virginia
eviewed and approved the protocol for this study before
xperimentation.
xperimental Protocol
even experimental groups (n 6/group, based on our most recent
tudy13) were compared using an isolated, whole blood–perfused,
entilated rabbit lung model (model TIS3862; Kent Scientific,
itchfield, Conn). All groups were reperfused for 120 minutes
fter 18 hours of cold ischemia at 4°C (see Table 1 for the
xperimental protocol for each group). We used 4-(3-[6-amino-9-
5-cyclopropylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-
urin-2-yl]-prop-2-ynyl)-piperidine-1-carboxylic acid methyl ester,
TL-313, a gift from Adenosine Therapeutics, LLC (Charlottesville,
a), as a potent, selective activator of the A2AR, and 4-(2-[7-amino-
-[2-furyl][1,2,4]triazolo[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)
henol, ZM 241385 (Tocris, Ellisville, Mo), as a selective A2AR
ntagonist. ATL-313 and ZM 241385 were dissolved in saline.
ung donors undergoing pretreatment received an intravenous
njection of the drug (ATL-313 [100 nmol/L] or ATL-313 [100
mol/L]  ZM 241385 [100 nmol/L] [note: drug concentrations
re final concentrations in blood determined by calculations based
n blood volume/kilogram]) 1 hour before harvest. When given
uring reperfusion (ATL-313 [100 nmol/L] or ATL-313 [100
mol/L]  ZM 241385 [100 nmol/L]), the respective drugs were
dministered to whole blood at the beginning of reperfusion. In the
roup receiving ATL-313 in the lung preservation solution, the
TL-313 was added to the preservation solution at 100 nmol/L.
he chosen dose of A2AR agonists and antagonists was based on
revious experiments.14-17
Harvest procedure. New Zealand White rabbits of both
exes (3.0 –3.5 kg) were randomly assigned to 7 experimental
roups. Intramuscular ketamine (50 mg/kg) and xylazine (5
g/kg) was used to anesthetize each animal. Tracheal intuba-
ion was performed via a tracheostomy and mechanical venti-
ation (model RSP1002; Kent Scientific, Litchfield, Conn) was
nstituted with room air at a respiratory rate of 30 breaths/min.
median sternotomy and thymectomy were performed. After
he pericardium was opened, the pulmonary artery (PA) and the
orta were dissected free and encircled. A purse-string suture
as then placed in the right ventricular outflow tract and
ntravenous heparin was administered (1000 U/kg). The PA was
hen injected with 30 g of prostaglandin E1, and the venae
avae were ligated to initiate ischemia 5 minutes after heparin
dministration. The PA was then cannulated through a right
entriculotomy. After the left ventricle was vented through a
eft ventriculotomy and the aorta was ligated, 100 mL/kg of
erfadex (Vitrolife, Kungsbacka, Sweden) preservation solu-
ion was infused into the PA at 30 cm H2O pressure at 4°C.
opical cooling was achieved with cold saline solution slush.
he left atrium was cannulated through the left ventriculotomy
and Cardiovascular Surgery ● Volume 135, Number 1 157
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1
TXith an outflow catheter. The lung– heart block was excised.
he lungs were then inflated and stored at 4°C for 18 hours.
Reperfusion procedure. After harvest, the lung–heart block
as suspended from a force transducer and ventilation was initi-
ted with a gas mixture of 95% oxygen and 5% carbon dioxide
model RSP1002, Kent Scientific). All groups underwent 120
inutes of whole-blood perfusion. Atelectasis was grossly elimi-
ated by administering one breath of approximately 30 cm H2O
ositive end-expiratory pressure once per minute in the first 5
inutes of the stabilization period. Lungs were ventilated at a
onstant tidal volume of 10 mL/kg with 3 cm H2O of positive
nd-expiratory pressure at a rate of 30 breaths/min. The PA and the
utflow catheters connected the lung–heart block to a venous
lood reperfusion circuit. New Zealand White rabbits served as
resh venous blood donors. Blood was circulated through a pedi-
tric oxygenator set to deoxygenate the blood and add carbon
ioxide to simulate venous blood (PO2  60 mm Hg/PCO2  60
m Hg). The lungs were subsequently perfused via the PA can-
ula at 60 mL/min with “venous” blood at 37°C.
hysiologic Parameters
ecordings of PA pressure and compliance were collected by a
ynamic data acquisition program (DASYLab, DASYTEC, USA.
edford, NH). Pulmonary venous blood samples were collected
or blood gas analysis (Bayer 348 pH/Blood Gas Analyzer; Bayer
orp, E Walpole, Mass) at 15, 30, 60, 90, and 120 minutes after
nitiation of reperfusion.
ung Wet/Dry Weight Ratio
ung wet/dry weight ratios were used as a measure of pulmonary
dema. Samples of right lower lobe lung tissue were blotted and
eighed immediately after 120 minutes of reperfusion. These
amples were desiccated under vacuum at 55°C until a stable dry
eight was achieved.
ung Tissue Myeloperoxidase
yeloperoxidase (MPO) assay was performed on lung tissue to
ABLE 1. Summary of study protocol (n  6 per group)
roup Treatment
Pretreat
donor animal
None
ATL313 ✓
ATL313
ATL313
ATL313 ✓
ZM 241385  ATL313 ✓
ZM 241385  ATL-313 ✓
A, Pulmonary artery; MPO, myeloperoxidase; TNF-, tumor necrosis facuantify neutrophil sequestration as previously described.17 t
58 The Journal of Thoracic and Cardiovascular Surgery ● Januronchoalveolar Lavage
ronchoalveolar lavage (BAL) was performed on all lungs after
he reperfusion period ended. The right upper and middle lobes
ere isolated and lavaged with 10 mL of normal saline. The BAL
uid was then centrifuged at 1500g for 5 minutes at 4°C. The
upernatant was snap-frozen for subsequent cytokine analysis.
nzyme-linked Immunosorbent Assay
he protein levels of tumor necrosis factor  (TNF-) in BAL
uid were examined with a TNF- enzyme-linked immunosorbent
ssay (ELISA) purchased from BD Biosciences (San Diego, Calif)
nd performed according to manufacturer directions. Samples
ere run in triplicate.
ung Injury Score
blinded pathologist graded each lung sample after appropriate
issue processing and staining (hematoxylin and eosin). Each sam-
le was graded on the basis of the number of macrophages, amount
f interstitial infiltrate, and percentage of alveolae affected by
brin deposition. Each of these three categories was then given a
core of 0 to 3, resulting in a possible score ranging from 0 for
ninjured lungs to 9 for the most severely injured lungs.
tatistics
alues were expressed as the mean standard deviation. Analysis of
ariance (ANOVA) was used to determine whether significant differ-
nces existed between groups. The Tukey honest significant differ-
nce multiple-comparison test was used to determine which groups
ere significantly different when the ANOVA results were signifi-
ant. Repeated-measures analysis of variance was performed and
ltimately allowed us to conclude that PA pressure, lung compliance,
nd oxygenation change over time and depend on group. The test for
etween-subject effects was significant, which implies significance in
he aforementioned variables between groups.
esults
hysiologic Measurements
retreatment of donor lungs with ATL-313 and the adminis-
ethod of treatment
End points
studied
retreat preserved lung
(flush)
During
reperfusion
PA pressure,
pulmonary
compliance,
lung
histology,
MPO activity,
TNF-, wet/
dry weight
✓
✓
✓
✓M
Pration of ATL-313 during reperfusion (group 5) resulted in
ary 2008
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TXignificant decreases in PA pressure compared with all groups
P .05) except group 4 (ATL-313, reperfusion; P .32). No
ignificant differences in PA pressure were observed between
ABLE 2. Lung function
roup PA pressure 15 min
Control 28.3 1.0†‡§ 25.7
Pretreatment (ATL
313)
19.0 1.8* 16.3
Flush (ATL 313) 27.3 1.0†‡§ 25.8
Reperfusion (ATL
313)
21.2 1.2*§ 16.0
Pretreatment and
reperfusion (ATL
313)
16.7 1.2*‡ 14.2
Pretreatment (ATL
313 ZM 243185)
27.2 2.8†‡§ 26.5
Pretreatment and
reperfusion (ATL 313
ZM 243185)
26.8 1.5†‡§ 25.0
roup Pulmonary compliance 15 min 3
Control 6.42 0.09†‡§ 5.93
Pretreatment (ATL
313)
6.90 0.14*§ 6.62
Flush (ATL 313) 6.43 0.08†‡ 5.88
Reperfusion (ATL
313)
6.82 0.12* 6.63
Pretreatment and
reperfusion (ATL
313)
6.95 0.19* 6.85
Pretreatment (ATL
313 ZM 243185)
6.20 0.24†‡§ 5.85
Pretreatment and
reperfusion (ATL 313
ZM 243185)
6.40 0.14†‡§ 5.82
roup PaO2 15 min 30
Control 524.3 9.1†§ 550.8
Pretreatment (ATL
313)
578.7 10.8*‡§ 600.5
Flush (ATL 313) 525.5 8.5†‡§ 547.2
Reperfusion (ATL
313)
550.5 7.7†§ 584.2
Pretreatment and
reperfusion (ATL
313)
669.7 20.3*†‡ 695.8
Pretreatment (ATL
313 ZM 243185)
532.7 29.2†§ 545.7
Pretreatment and
reperfusion (ATL 313
ZM 243185)
525.7 8.0†§ 550.3
A, Pulmonary artery; PaO2, arterial oxygen saturation. Data are reported
airwise comparisons between specific groups (Tukey honest significant d
P  .05 versus reperfusion (ATL-313); §P  .05 versus pretreatment andhe administration of ATL-313 during reperfusion alone l
The Journal of Thoracicgroup 4) versus ATL-313 pretreatment alone (group 2), al-
hough these interventions did result in significant decreases in
A pressure versus control (P  .01). Significant increases in
60 min 90 min 120 min
4†‡§ 25.0 0.6†‡§ 26.7 1.2†‡§ 32.8 1.2†‡§
0* 19.0 1.0*§ 19.5 1.0* 22.2 1.2*‡
0†‡§ 24.8 0.9†‡§ 27.3 0.8†‡§ 31.2 1.4†‡§
4* 16.8 1.7* 17.5 1.2* 18.5 1.5*†
7* 16.5 1.0*† 17.7 0.8* 19.8 1.9*
6†‡§ 26.8 2.3†‡§ 29.3 2.3†‡§ 31.6 2.1†‡§
9†‡§ 24.2 1.2†‡§ 25.2 1.2*†‡§ 29.3 1.9†‡§
60 min 90 min 120 min
0†‡§ 5.58 0.12†‡§ 5.30 0.14†‡§ 4.93 0.08†‡§
9*§ 6.42 0.13*§ 6.18 0.17*§ 5.46 0.16*§
8†‡ 5.70 0.11†‡ 5.43 0.10†‡ 5.07 0.08†‡
0* 6.38 0.13*§ 6.18 0.18*§ 5.87 0.20*§
0*† 6.70 0.09*‡ 6.58 0.13*†‡ 6.25 0.15*†‡
2†‡§ 5.55 0.32†‡§ 5.28 0.35†‡§ 5.08 0.33†‡§
2†‡§ 5.68 0.13†‡§ 5.45 0.11†‡§ 5.12 0.12†‡§
60 min 90 min 120 min
†‡§ 552.5 7.9†‡§ 539.5 6.7†‡§ 529.7 2.7†‡§
*§ 583.8 11.9*§ 580.2 8.0*§ 563.8 7.7*§
‡§ 553.5 7.4†‡ 537.7 9.9†‡§ 527.0 5.1†‡§
§ 581.0 5.8*§ 575.2 5.4*§ 569.2 2.8*§
*†‡ 686.3 12.9*†‡ 663.7 20.0*†‡ 655.7 13.7*†‡
†‡§ 547.3 32.9†‡§ 534.0 35.1†‡§ 521.8 38.2†‡§
†‡§ 553.7 10.6†‡§ 541.7 6.3†‡§b 525.3 7.1†‡§
ch time point as mean standard deviation. All ANOVA P values  .000.
ce test): *P  .05 versus control; †P  .05 versus pretreatment (ATL-313);
rfusion (ATL-313).30 min
 1.
 1.
 1.
 1.
 1.
 2.
 0.
0 min
0.1
0.0
0.0
0.1
0.1
0.2
0.1
min
11.1
16.9
9.3†
6.7*
15.7
31.7
10.6
at ea
ifferenung compliance and oxygenation were observed with pretreat-
and Cardiovascular Surgery ● Volume 135, Number 1 159
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1
TXent of donor lungs with ATL-313 and the concurrent admin-
stration of ATL-313 during reperfusion (group 5) versus all
ther groups (all P  .05). The concurrent administration of
TL-313 with its antagonist, ZM 241385, nullified the phys-
ologic effects of ATL-313 pretreatment and its administration
ith reperfusion. Pairwise comparisons between groups at
pecific time points (ie, at 15, 30, 60, 90, and 120 minutes) are
ound in Table 2.
LISA for TNF-
LISA was used to evaluate the effect of the timing of
TL-313 administration on the quantity TNF- in BAL
uid (Figure 1). ATL-313 pretreatment and its concurrent
dministration during reperfusion (group 5) resulted in the
reatest decrease in TNF- levels (42%) versus control (P
.01). This decrease in TNF- was abolished by the
imultaneous administration of ZM 241385 (group 7). Pre-
reatment with ATL-313 alone (group 2) and ATL-313
reatment during reperfusion alone (group 4) resulted in a
5% and 40% decrease in TNF-  levels, respectively,
ompared with control (both P  .01). The administration
f ATL-313 in the preservation solution (group 3) did not
ffect TNF- levels versus control (P  .99).
PO Activity
PO activity was used as an indicator of lung tissue neu-
rophil sequestration (Figure 2). ATL-313 pretreatment and
oncomitant ATL-313 treatment during reperfusion (group
) led to a 48% reduction in MPO activity compared with
Figure 1. BAL TNF- levels. All groups were compared
5. *P < .01.ontrol (P .01). ATL-313 pretreatment alone (group 2) or p
60 The Journal of Thoracic and Cardiovascular Surgery ● Janudministration during reperfusion alone (group 4) reduced
PO levels (39% and 44%, respectively) versus control (P
.01), although no significant differences were seen when
hese groups were compared with group 5 (concurrent ad-
inistration of ATL-313 during pretreatment and reperfu-
ion). The decrease in MPO activity observed with ATL-
13 pretreatment and with its concurrent administration
uring reperfusion was blocked by the administration of the
2AR antagonist, ZM 241385.
et/Dry Analysis
et/dry ratios were examined as an indicator of pulmonary
dema (Figure 3). Pretreatment of donor lungs with ATL-313
group 2) resulted in a 28% reduction in the wet/dry ratio
ersus control (P  .01). Compared with control, ATL-313
reatment during reperfusion alone (group 4) reduced the wet/
ry ratio by 32% (P  .01). ATL-313 administration during
eperfusion along with pretreatment (group 5) led to the great-
st reduction in wet/dry ratio versus control (37%; P  .01).
TL-313 was protective against the development of pulmo-
ary edema when given before ischemia and/or with reperfu-
ion. This protective effect was lost with the concurrent ad-
inistration of the A2AR antagonist, ZM 241385. The addition
f ATL-313 to the preservation solution (group 3) failed to
ignificantly reduce edema.
ung Histologic Condition
verall lung histologic condition (Figure 4) was most im-
control. Lowest TNF- levels were observed in groupwithroved and lung injury severity score (Table 3) most de-
ary 2008
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TXreased in group 5 (lungs pretreated with ATL-313 and also
reated during reperfusion) compared with all other groups
ncluding group 2 (ATL-313 pretreatment) and group 4
ATL-313 treatment during reperfusion) (all P  .05). Al-
Figure 2. Lung tissue MPO. All groups were compared
5. *P < .01. OD, Optimal dose.
Figure 3. Wet/dry analysis. All groups were compared
5. *P < .01.
The Journal of Thoracichough the total lung injury severity score was not different
etween group 2 (ATL-313 pretreatment) and group 4
ATL-313 treatment during reperfusion), pretreatment
group 2) significantly decreased the number of macro-
control. Lowest MPO activity was observed in group
control. Lowest wet/dry ratio was observed in groupwithwithand Cardiovascular Surgery ● Volume 135, Number 1 161
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1
TXhages in the alveolar space compared with treatment dur-
ng reperfusion alone (group 4). The severity of interstitial
nfiltrate, however, was similar between these two groups.
he administration of the A2AR antagonist, ZM 241385,
imultaneously with ATL-313 during pretreatment (group
) and during pretreatment and reperfusion (group 7) re-
ulted in similar scores compared with control (all P  .05)
s did the administration of ATL-313 with the preservation
olution (data not shown).
igure 4. Representative hematoxylin–eosin sections of lung tis-
ue. A, Group 5 (ATL-313 pretreatment and administration during
eperfusion). B, Group 1 (control).
ABLE 3. Lung severity score
roup Interstitial infiltrate
Control 2.17  0.52*
Pretreatment
(ATL 313)
1.33 0.26*
Reperfusion (ATL
313)
1.08 0.21
Pretreatment and
reperfusion
(ATL 313)
0.92 0.20
 .05 in all pairwise comparisons versus control; *P  .05 in pairwise c
roup 4.
62 The Journal of Thoracic and Cardiovascular Surgery ● Januiscussion
denosine, widely known for its anti-inflammatory proper-
ies, exerts a protective role against the development of
schemia-induced cell injury.5,6 Activation of the A2AR
ubtype has been specifically associated with protection
gainst the development of LIRI.8,18 Studies to date have
evealed the benefits of pharmacologic A2AR activation
uring lung reperfusion associated with inhibition of in-
ammation, but have not previously examined the effect of
reating the host animal with an A2A agonist before tissue
ransplantation. Growing evidence supports the concept that
schemic preconditioning, brief periods of ischemic insult
efore prolonged ischemia, protects against IR injury in
arious organ systems. The protection resulting from isch-
mic preconditioning is associated with increased levels of
xtracellular adenosine and thus provides the concept that
he pharmacologic activation of adenosine receptors before
schemia may confer protection against LIRI.11 It is notable,
owever, that ischemic preconditioning has been reported to
e due to activation of A1, A2B, or A3 receptors, and not A2A
eceptors. This is the first study to our knowledge that
pecifically investigates the effect of A2AR activation before
ung ischemia.
Our study demonstrates that A2AR activation before lung
schemia confers significant protection against the deterio-
ation of lung function seen during reperfusion. Improved
ung physiology seen with ATL-313 pretreatment correlated
ith significantly decreased levels of the potent proinflam-
atory cytokine, TNF-, pulmonary edema, neutrophil se-
uestration (decreased MPO), and preserved lung histology.
ot surprisingly, A2AR activation during reperfusion also
rovided significant protection against LIRI.8,19 More im-
ortant, clinically relevant and additive improvements in
xygenation and lung compliance were seen with the con-
omitant administration of ATL-313 before lung harvest
nd with reperfusion versus ATL-313 pretreatment alone or
dministration during reperfusion alone. The loss of protec-
ion observed with the administration of the A2AR antago-
ist, ZM 241385, with ATL-313 indicates that the mecha-
Macrophages Fibrin Total score
2.67 0.51* 1.58 0.66* 6.42 1.24*
0.92 0.21*† 0.08 0.21 2.5  0.45*
1.67 0.51*† 0.17 0.40 2.92 0.92*
0.08 0.21 0.0 0.0 1.0 0.44
rison versus group 5; †P  .05 in pairwise comparison of group 2 versusompaary 2008
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TXism of ATL-313 protection is specifically mediated via
2AR activation. Since A2AR activation is known to inhibit
he activation of leukocytes, the protection afforded by
retreating rabbits with ATL-313 may be due to inhibition
f resident leukocytes in the transplanted lung, whereas the
rotection observed during reperfusion is likely due to re-
uced adhesion and extravasation of leukocytes in blood or
eperfused lung. Of note, the temperature (4°C) of the
reservation solution may account for the lack of effect of
TL-313 in this solution.
This study also highlights the emerging therapeutic role
f simulating preconditioning pharmacologically by ex-
loiting different mediators of protection. The use of aden-
sine and A2AR agonists, such as ATL-313, is a logical
xtension of many intrinsic defense mechanisms inasmuch
s adenosine is known to accumulate in response to isch-
mia and hypoxia.20 Whereas the exact mechanisms of
rotection are complex and poorly understood, increased
evels of adenosine before a sustained ischemic event have
een shown to improve end-organ function in the liver,21
idney,22 and heart,23 although some of these effects are not
ediated by A2AR activation. Treatment with A2AR ago-
ists has also been associated with inhibition of inflamma-
ory cytokine release, reduction of IR-induced apoptotic
njury, and diminution of free radical production.18,24 In an
solated, buffer-perfused rat lung model, Yildiz and col-
eagues25 demonstrated that adenosine “preconditioning”
onferred similar protection against IR-induced pulmonary
asoconstrictor dysfunction, edema, and lipid peroxidation
s did their ischemic preconditioning protocol. Moreover,
he administration of the nonselective adenosine receptor
ntagonist, theophylline, abolished the protective effects of
schemic preconditioning, thereby implying adenosine’s
ritical role as a mediator of preconditioning. It has not yet
een determined whether a selective A2AR antagonist such
s ZM 241385 will block all of the preconditioning effects
f adenosine. Nitric oxide has also been described as a
rotective mediator in preconditioning, decreasing LIRI
ith 10 minutes of nitric oxide pretreatment at 15 ppm.
imitations of the use of adenosine and nitric oxide per se
s preconditioning agents are their cardiovascular side ef-
ects. Interestingly, A2AR activation has also been associ-
ted with enhanced production of nitric oxide in cultured
oronary artery cells.26
The role of inflammatory cells in the pathogenesis of IR
njury is unquestioned. A greater body of evidence further
upports the emerging role of donor alveolar macrophages
n early LIRI and its subsequent priming of other inflam-
atory cells such as neutrophils.27 Adenosine has also been
hown to decrease not only the release of TNF- and other
roinflammatory cytokines from macrophages but also the
ctivation of neutrophils from TNF- released from mac-
ophages.28 Moreover, A2AR activation also directly inter- p
The Journal of Thoraciceres with neutrophil-induced IR injury. Treatment of rats
ith the A2AR agonist, ATL-146e, resulted in decreased
xpression of the adhesion molecules P-selectin, intercellu-
ar adhesion molecule 1, and vascular cell adhesion mole-
ule 1 in renal29 and myocardial30 IR models. A2AR acti-
ation was shown to decrease the release of neutrophil
lastase and cytokine-induced neutrophil chemoattractant,
n effect that was blocked with the administration of the
2AR antagonist, ZM 241385. Again, the administration of
TL-313 in the current study did significantly attenuate
NF- levels in BAL fluid, although the specific sources of
NF- release were not examined. Interestingly, ATL-313
retreatment resulted in a significant decrease in the number
f macrophages seen on histologic examination compared
ot only with control but also with the administration of
TL-313 during reperfusion alone and may account, in part,
or the decreased levels of TNF- seen with pretreatment.
inimizing the quantity of macrophages may have also
mproved lung function by minimizing the respiratory burst
ctivity of macrophages. Although there is indirect evidence
f diminished neutrophil mediated injury with ATL-313,
ignificant decreases in neutrophil sequestration (decreased
PO) and interstitial infiltrate seen by lung histologic stud-
es support the anti-inflammatory properties of A2AR acti-
ation in our model of LIRI.
Aspects of A2AR agonism still require further elucida-
ion. The effect of A2AR agonism on T cells and natural
iller cells, known contributors to lung IR injury, were not
valuated in this study. A2AR agonism has, however, been
bserved to mitigate T cell–related interferon  production
nd secondary macrophage activation in inflamed tissue.31
he immunologic effect of A2AR agonism, especially in
erms of the immunosupressed transplant patient, also re-
uires further inquiry. A2AR agonists may also cause sys-
emic hypotension and thus potentially limit their clinical
pplicability.
The concept that IR injury is attenuated by A2AR pre-
reatment and that concurrent A2AR activation during reper-
usion further improves lung function is poorly described
et clinically relevant, despite the aforementioned uncer-
ainties. The elimination of the improvements observed with
2AR activation with the addition of a highly selective
2AR antagonist provides strong evidence that the mecha-
ism of protection is specifically mediated via A2AR acti-
ation. The specific downstream mediators of protection
onferred by pharmacologic adenosine preconditioning re-
ain elusive. Early evidence supports the activation of
itogen-activated protein kinase subtypes including extra-
ellular signal-related kinase 1/2, jun N terminal kinase1/2,
nd p38 and the attenuation of apoptosis as a few of the
ossible mechanisms of protection conferred by adenosine
eceptor activation before major ischemic insult.19,32 The
harmacologic activation of the A2AR along with optimized
and Cardiovascular Surgery ● Volume 135, Number 1 163
t
t
s
w
t
a
f
p
c
c
a
l
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
D
D
e
l
f
t
i
t
Cardiothoracic Transplantation Gazoni et al
1
TXiming of activation may prove to be an important therapeu-
ic intervention in attenuating the robust inflammatory re-
ponse after lung transplantation.
In conclusion, this report demonstrates that pretreatment
ith an A2AR agonist protects the lung against IR injury and
hat further improvements in oxygenation and lung compli-
nce occur with concurrent A2AR activation during reper-
usion. The ability to exploit and further characterize innate
hysiologic mechanisms of protection that minimize the
ontribution of inflammatory cells will likely prove to be
ritical in reducing the destructive consequences of LIRI
nd ultimately improve the care of patients with end-stage
ung disease.
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iscussion
r Mark J. Krasna (Towson, Md). What is the anti-inflammatory
ffect that you think ATL-313 has? Tell us what your view is.
Dr Gazoni. A2AR agonists significantly decrease the amount of
eukocyte activation and decrease the interaction of neutrophils,
or example, with endothelial cells. One of the mechanisms behind
hat is decreasing the expression of adhesion molecules such as
ntercellular adhesion molecule and P-selectin. These are some of
he few widely documented anti-inflammatory effects of the A R2A
gonists.
ary 2008
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Gazoni et al Cardiothoracic TransplantationDr Frank W. Sellke (Boston, Mass). I have a technical ques-
ion. You subjected the lungs to 18 hours of ischemia and then
eperfusion. Did you reperfuse with blood or with a crystalloid
olution?
Dr Gazoni. We reperfused with whole blood. After working on
his model for 2 years, I do not think I can handle seeing another
abbit. We actually have to exsanguinate 2 rabbits to reperfuse the
arvested lung. So for every lung that we get data from there are
ctually 3 rabbits that are put to death total.
Dr Sellke. That was my next question. Did you kill the rabbits
ight before you were going to reperfuse the lungs or did you kill
hem at the same time and freeze the blood?
Dr Gazoni. As I am priming the reperfusion apparatus, I
ctually administer anesthesia to the blood donors with a combi-
ation of ketamine, xylazine, and vecuronium. As I open up the
hest, the heart is still beating and I then cannulate the right
trium/ventricle. The blood then goes directly to the reperfusionThe Journal of ThoracicDr Sellke. One other question has to do with statistics. Did you
o a multiple comparison test, or how did you compare the
ifferent groups? If you have 6 groups you have to have tremen-
ous differences to reach statistical significance.
Dr Gazoni. We performed an ANOVA initially to see that
here are actual differences between all groups throughout all time
eriods. All ANOVA tests were significant. The Tukey honest
ignificant difference multiple-comparison test was then used to
etermine which groups were significantly different.
Dr David H. Harpole (Durham, NC). This is a very elegant
echnique. The only question I have is very simple. I read the paper
nd read this, and I could not exactly see. You had standard
eviations. How many animals were in each group?
Dr Gazoni. Six. This is the third experiment I have performed
ith this model. I have probably harvested and reperfused about
00 lungs. By the time I did this experiment, which is the last
xperiment I have done with this model, I have gotten the tech-TXpparatus. nique down fairly well.
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